NVP-BGJ398 phosphate

Research use only, not for human use.

NVP-BGJ398 phosphate (Infigratinib phosphate, BGJ398 phosphate) is a potent, selective pan-FGFR inhibitor.

NVP-BGJ398 phosphate (Infigratinib phosphate, BGJ398 phosphate) is a potent, selective pan-FGFR inhibitor with IC50 of 0.9/1.0/1.4/60 nM for FGFR1/2/3/4, also shows high potenct against mutant FGFR3-K650E with IC50 of 4.9 nM; inhibits the proliferation of the FGFR1-, FGFR2-, and FGFR3-dependent BaF3 cells with IC50 of low nanomolar range; shows significant antitumor activity in RT112 bladder cancer xenografts models overexpressing wild-type FGFR3, significantly inhibits the growth of FGFR2-mutated endometrial cancer xenograft models, also ameliorates FGF23-mediated hypophosphatemic rickets in mouse models.Blood Cancer Phase 2 Clinical.

Infigratinib phosphate inhibits FGFR1, FGFR2, and FGFR3 with IC50=~1 nM, FGFR3K650E with IC50=4.9 nM, and FGFR4 with IC50=60 nM. IC50 values for all other kinases are in the μM range (FYN, LCK, YES, and ABL, IC50=1.9, 2.5, 1.1, and 2.3 μM, respectively) except for VEGFR2, KIT, and LYN, which are inhibited at submicromolar concentrations (IC50=0.18, 0.75, and 0.3 μM, respectively). Infigratinib inhibits the proliferation of the FGFR1-, FGFR2-, and FGFR3-dependent BaF3 cells with IC50 values which are in the low nanomolar range and comparable to those observed for the inhibition of the receptors kinase activity in the enzymatic assay. For the remaining cells, all IC50 values are greater than 1.5 μM except for VEGFR2 (IC50 1449 and 938 nM), for which there is at least a 400-fold selectivity versus FGFR1, FGFR2, and FGFR3. Infigratinib (ranging between 1 nM and 10 μM) is potent at inhibiting cell growth of FGFR2-mutant endometrial cancer cells.

Infigratinib is administered to athymic nude mice implanted subcutaneously with RT112/luc1 tumors: either as a 5 mg/kg intravenous bolus in NMP/PEG200 (1:9, v/v) or orally by gavage as a suspension in PEG300/D5W (2:1, v/v) at a 20 mg/kg dose. The relevant pharmacokinetic (PK) parameters indicate that the oral bioavailability of Infigratinib in this study is 32%. After intravenous dosing, Infigratinib shows a rapid distribution from the vascular compartment into the peripheral tissues, translating into a high volume of distribution (26 L/kg). The plasma clearance is high at 3.3 L/h/kg (61% of liver blood flow). The ratio of tumor to plasma after oral dosing based on AUC is determined to be 10. Infigratinib (30 mg/kg) significantly inhibits the growth of FGFR2-mutated endometrial cancer xenograft models.

Infigratinib phosphate | BGJ-398 phosphate

Angiogenesis

FGFR

FGFR

Cancer

Blood cancer

1310746-10-1

658.4738

C26H34Cl2N7O7P

>98% (HPLC)

10 mM in DMSO

CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl.OP(=O)(O)O

Urea, N'-(2,6-dichloro-3,5-dimethoxyphenyl)-N-[6-[[4-(4-ethyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]-N-methyl-, phosphate (1:1)

(-20℃)

With Ice Pack

≥ 2 years